Listen to testimonies from leading professionals in the medical field
1. Doctor Jay Ellenby former president of Greater Miami and State of Florida Societies of plastic surgeons
2. Professor Angus Dalgleish Chairman of Oncology St Georges Hospital London
The Research
During 2005, two sets of clinical trials were undertaken in respect of the technology by the department of plastic surgery of a leading US university, and Stephens and Associates, an independent company which specialises in product safety evaluation and toxicology, with research centres in Texas and Colorado
Both trials were double blind randomised studies, with a placebo (A leading competitive product) applied on one side of the face and Entre Dermä Night Cream on the other.
The trial conducted by Stephens & Associates tested 20 women with mild to moderate facial wrinkling, over a 4 week period.
The results of the test were conclusive, showing that the company's cream performed significantly better in treating wrinkles and mottled pigmentation. In addition the subjects felt the company's product made their skin feel better and look better as well.
In the trial conducted by a leading University 10 women were scheduled to undergo facial plastic surgery following the trial. The trial took place over 30 days. On completion of such facial plastic surgery, the surgically removed skin was subject to a biopsy, undertaken by an independent pathologist. The Biopsies demonstrated that the active collagen and elastin had been transported through the skin.
The results of both sets of tests were conclusive, showing that the company's night cream performed significantly better in treating wrinkles and mottled pigmentation.
Entre Dermä
The company's first product range using SomaZoneä technology will be marketed under the name Entre Dermä. The range will comprise of general skincare and cleansing products, and will include a day cream and a night cream which focus on the application of derived collagen for skin firmness.
Four new product ranges utilising the transdermal qualities of the biopolymer are planned to follow the Entre Dermä products link to www.entrederm.com site.
SomaZoneä
SomaZoneä is a substance known as a biopolymer. It is the result of years of research in transdermal delivery. In Entre Dermä Skincare's Night and Day Creams, active ingredients such as collagen, are attached to the SomaZoneä molecule which enables the direct delivery of these ingredients through the surface of the skin.
SomaZoneä allows large molecules to squeeze through the outer layers of skin and be delivered to where they are vitally needed. Until now, substances with a high molecular weight such as collagen, could not be reliably delivered into the skin without a needle.
The technology behind SomaZoneä was developed from research into the transdermal delivery of insulin for diabetics. Our parent company, Transdermal Sciences PLC, holds a patent for this transdermal drug delivery system.
SomaZoneä is our patent-pending process that combines this biopolymer backbone with active ingredients. SomaZone'sä interdermal delivery of these ingredients, such as collagen, ceramides and hyaluronic acid, ushers in a future of increased effectiveness to the world of cosmetics.
